Identification

Name
Paroxetine
Accession Number
DB00715
Type
Small Molecule
Groups
Approved, Investigational
Description

Paroxetine hydrochloride and paroxetine mesylate belong to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a complete listing of side effects). Side effects generally occur during the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Paroxetine hydrochloride and mesylate are considered therapeutic alternatives rather than generic equivalents by the US Food and Drug Administration (FDA); both agents contain the same active moiety (i.e. paroxetine), but are formulated as different salt forms. Clinical studies establishing the efficacy of paroxetine in various conditions were performed using paroxetine hydrochloride. Since both agents contain the same active moiety, the clinical efficacy of both agents is thought to be similar. Paroxetine may be used to treat major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD) and premenstrual dysphoric disorder (PMDD). Paroxetine has the most evidence supporting its use for anxiety-related disorders of the SSRIs. It has the greatest anticholinergic activity of the agents in this class and compared to other SSRIs, paroxetine may cause greater weight gain, sexual dysfunction, sedation and constipation.

Structure
Thumb
Synonyms
  • (-)-(3S,4R)-4-(P-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
  • (3S-trans)-3-((1,3-Benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
  • Paroxetina
  • Paroxetine
  • Paroxetinum
External IDs
BRL-29060
Product Ingredients
IngredientUNIICASInChI Key
Paroxetine hydrochloride3I3T11UD2S78246-49-8GELRVIPPMNMYGS-RVXRQPKJSA-N
Paroxetine hydrochloride hemihydrateX2ELS050D8110429-35-1MQZOATSIFWSKKT-OASXIEIISA-N
Paroxetine mesylateM711N184JE217797-14-3SHIJTGJXUHTGGZ-RVXRQPKJSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act ParoxetineTablet10 mgOralActavis Pharma Company2005-03-14Not applicableCanada
Act ParoxetineTablet20 mgOralActavis Pharma Company2005-03-14Not applicableCanada
Act ParoxetineTablet30 mgOralActavis Pharma Company2005-03-14Not applicableCanada
Auro-paroxetineTablet20 mgOralAuro Pharma Inc2012-07-24Not applicableCanada
Auro-paroxetineTablet10 mgOralAuro Pharma Inc2012-07-24Not applicableCanada
Auro-paroxetineTablet30 mgOralAuro Pharma Inc2012-07-24Not applicableCanada
Bio-paroxetineTablet20 mgOralBiomed Pharma2016-12-21Not applicableCanada
Bio-paroxetineTablet30 mgOralBiomed Pharma2016-12-21Not applicableCanada
Bio-paroxetineTablet10 mgOralBiomed Pharma2016-12-21Not applicableCanada
BrisdelleCapsule7.5 mg/1OralSebela Pharmaceuticals Inc.2017-05-23Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-paroxetineTablet10 mgOralApotex Corporation2003-10-24Not applicableCanada
Apo-paroxetineTablet20 mgOralApotex Corporation2003-10-24Not applicableCanada
Apo-paroxetineTablet30 mgOralApotex Corporation2003-10-24Not applicableCanada
ParoxetineTablet, film coated20 mg/1OralPreferreed Pharmaceuticals Inc.2007-04-13Not applicableUs
ParoxetineTablet, film coated20 mg/1OralAurobindo Pharma2007-07-25Not applicableUs
ParoxetineTablet, film coated, extended release37.5 mg/1OralLupin Pharmaceuticals2017-01-20Not applicableUs
ParoxetineTablet, film coated40 mg/1OralPd Rx Pharmaceuticals, Inc.2008-03-24Not applicableUs00378 7004 93 nlmimage10 b932dcf6
ParoxetineTablet, film coated10 mg/1OralPreferreed Pharmaceuticals Inc.2012-12-20Not applicableUs
ParoxetineTablet, film coated10 mg/1OralPreferreed Pharmaceuticals Inc.2017-06-06Not applicableUs
ParoxetineTablet, film coated10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-03-07Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ParoxetineTablet, film coated20 mg/1OralProficient Rx LP2014-11-01Not applicableUs
International/Other Brands
Aropax / PAXILCR / Sereupin / Seroxat / Seroxat CR
Categories
UNII
41VRH5220H
CAS number
61869-08-7
Weight
Average: 329.3654
Monoisotopic: 329.142721716
Chemical Formula
C19H20FNO3
InChI Key
AHOUBRCZNHFOSL-YOEHRIQHSA-N
InChI
InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1
IUPAC Name
(3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
SMILES
FC1=CC=C(C=C1)[[email protected]@H]1CCNC[[email protected]]1COC1=CC2=C(OCO2)C=C1

Pharmacology

Indication

Labeled indications include: major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD). Unlabeled indications include: eating disorders, impulse control disorders, vasomotor symptoms of menopause, obsessive-compulsive disorder (OCD) in children, and mild dementia-associated agitation in nonpsychotic individuals. Brisdelle, which consists of paroxetine mesylate is indicated for the treatment of moderate to severe vasomotor symptoms (like hot flashes) associated with menopause.

Structured Indications
Pharmacodynamics

Paroxetine, an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) type, has no active metabolites and has the highest specificity for serotonin receptors of all the SSRIs. It is used to treat depression resistant to other antidepressants, depression complicated by anxiety, panic disorder, social and general anxiety disorder, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder, premature ejaculation, and hot flashes of menopause in women with breast cancer. In human platelets, paroxetine blocks the uptake of serotonin. It has weak effects on norepinephrine and dopamine neuronal reuptake. In vitro radioligand binding studies indicate that paroxetine has little affinity for muscarinic alpha1-, alpha2-, beta-adrenergic-, dopamine (D2)-, 5-HT1-, 5-HT2-, and histamine (H1)-receptors.

Mechanism of action

Paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake. Paroxetine likely inhibits the reuptake of serotonin at the neuronal membrane, enhances serotonergic neurotransmission by reducing turnover of the neurotransmitter, therefore it prolongs its activity at synaptic receptor sites and potentiates 5-HT in the CNS; paroxetine is more potent than both sertraline and fluoxetine in its ability to inhibit 5-HT reuptake. Compared to the tricyclic antidepressants, SSRIs have dramatically decreased binding to histamine, acetylcholine, and norepinephrine receptors. The mechanism of action for the treatment of vasomotor symptoms is unknown.

TargetActionsOrganism
ASodium-dependent serotonin transporter
inhibitor
Human
USodium-dependent noradrenaline transporter
inhibitor
Human
U5-hydroxytryptamine receptor 2A
other/unknown
Human
NMuscarinic acetylcholine receptor M1
antagonist
Human
NMuscarinic acetylcholine receptor M2
antagonist
Human
NMuscarinic acetylcholine receptor M3
antagonist
Human
NMuscarinic acetylcholine receptor M4
antagonist
Human
NMuscarinic acetylcholine receptor M5
antagonist
Human
Absorption

Paroxetine hydrochloride is slowly, but completely absorbed following oral administration. Paroxetine mesylate salt is also completely absorbed after oral dosing. The oral bioavailability appears to be low due to extensive first-pass metabolism. Paroxetine hydrochloride oral tablets and suspension are reportedly bioequivalent. Absorption of either salt form is not substantially affected by food. Peak concentrations of Brisbelle (mesylate salt) were reached at 6 hours (3 to 8 hours range). Steady state Cmax was 13.10 ng/mL. The steady state AUC (0-last) was 237 hr*ng/mL. Paroxetine mesylate generally follows non-linear pharmacokinetics because CYP2D6, the enzyme that is part responisible for paroxetine metabolism, is readily saturable.

Volume of distribution

3.1-28 L/kg observed in animal studies. Paroxetine distributes throughout the body, including the central nervous system, with only 1% remaining in the plasma.

Protein binding

~ 95% bound to plasma proteins.

Metabolism

Paroxetine is extensively metabolized after oral administration, likely in the liver. The main metabolites are polar and conjugated products of oxidation and methylation, which are readily eliminated by the body. The predominant metabolites are glucuronic acid and sulfate conjugates. Paroxetine metabolites do not possess significant pharmacologic activity (less than 2% that of parent compound). Paroxetine is metabolized by cytochrome P450 (CYP) 2D6. Enzyme saturation appears to account for the nonlinear pharmacokinetics observed with increasing dose and duration of therapy.

Route of elimination

Approximately 64% of a 30 mg oral solution of paroxetine was excreted in the urine with 2% as the parent compound and 62% as metabolites. Approximately 36% of the dose was excreted in the feces (via bile), mostly as metabolites and less than 1% as parent compound.

Half life

21-24 hours

Clearance
Not Available
Toxicity

LD50=500mg/kg (orally in mice). Symptoms of overdose include: coma, dizziness, drowsiness, facial flushing, nausea, sweating, tremor, vomiting. Side effects include: nervous system effects such as asthenia, somnolence, dizziness, insomnia, tremor, and nervousness; GI effects such as nausea, decreased appetite, constipation, diarrhea, and dry mouth; impotence, ejaculatory dysfunction (principally ejaculatory delay), and other male genital disorders; female genital disorders (principally anorgasmia or difficulty reaching climax/orgasm); and sweating. Discontinuation syndrome may occur with abrupt withdrawal. Symptoms of discontinuation syndrome include flu-like symptoms, insomnia, nausea, imbalance, sensory changes, and hyperactivity.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Multidrug resistance protein 1---(C;C) / (C;T)C AlleleEffect Directly StudiedPatients with this genotype have an increased likelihood of remission when using paroxetine to treat major depressive disorder.Details
Cytochrome P450 2D6CYP2D6*3Not Available2549delAEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of paroxetine.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableA alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of paroxetine.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of paroxetine.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of paroxetine.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, alternative drug or dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*3Not AvailableG alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of paroxetine.Details
Cytochrome P450 2D6CYP2D6*4Not Available3877G>AEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of paroxetine.Details

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Paroxetine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Paroxetine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Paroxetine.Experimental
AbirateroneThe serum concentration of Paroxetine can be increased when it is combined with Abiraterone.Approved
AcarboseParoxetine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcenocoumarolParoxetine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Paroxetine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Paroxetine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Acetophenazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Paroxetine.Approved
Acetylsalicylic acidParoxetine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Paroxetine.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Paroxetine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Paroxetine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Paroxetine.Approved, Investigational
AlaproclateParoxetine may increase the serotonergic activities of Alaproclate.Experimental
AlbiglutideParoxetine may increase the hypoglycemic activities of Albiglutide.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Paroxetine.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Paroxetine.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Paroxetine.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Paroxetine.Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Paroxetine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Paroxetine.Approved
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Paroxetine.Experimental, Illicit
AlphaprodineAlphaprodine may increase the serotonergic activities of Paroxetine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Paroxetine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Paroxetine.Approved, Withdrawn
AmineptineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amineptine.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Paroxetine.Approved, Withdrawn
AmiodaroneParoxetine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Paroxetine.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Paroxetine.Approved, Investigational
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Paroxetine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Paroxetine.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Paroxetine.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Paroxetine.Approved
AnagrelideParoxetine may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Paroxetine.Approved
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Paroxetine.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Paroxetine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Paroxetine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Paroxetine is combined with Aripiprazole.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Paroxetine.Approved, Investigational
Arsenic trioxideParoxetine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherParoxetine may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Paroxetine.Approved
AsenapineParoxetine may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Paroxetine.Approved, Withdrawn
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Paroxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Azaperone.Investigational, Vet Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Paroxetine.Approved
AzithromycinParoxetine may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Paroxetine.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Paroxetine.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Paroxetine.Illicit
BedaquilineParoxetine may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololThe serum concentration of Befunolol can be increased when it is combined with Paroxetine.Experimental
BendroflumethiazideParoxetine may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Paroxetine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Paroxetine is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Paroxetine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Paroxetine.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Paroxetine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Paroxetine.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Paroxetine.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Paroxetine.Approved
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Paroxetine.Approved
BezitramideBezitramide may increase the serotonergic activities of Paroxetine.Experimental, Illicit, Withdrawn
BifeprunoxThe risk or severity of adverse effects can be increased when Paroxetine is combined with Bifeprunox.Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Paroxetine.Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Paroxetine.Investigational
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Paroxetine.Approved
BortezomibThe metabolism of Bortezomib can be decreased when combined with Paroxetine.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Paroxetine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Paroxetine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Paroxetine.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Paroxetine.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Paroxetine.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Paroxetine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Paroxetine.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Paroxetine is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Paroxetine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Paroxetine.Approved, Investigational, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Paroxetine.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Paroxetine.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Paroxetine.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Paroxetine.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Paroxetine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Paroxetine.Approved
BuspironeBuspirone may increase the serotonergic activities of Paroxetine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Paroxetine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Paroxetine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Paroxetine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Paroxetine.Approved
ButaperazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Paroxetine.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Paroxetine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Paroxetine.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Paroxetine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Paroxetine.Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Paroxetine.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Paroxetine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Paroxetine.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Paroxetine.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Paroxetine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Paroxetine.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Paroxetine.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Paroxetine.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Paroxetine.Approved, Investigational
CelecoxibParoxetine may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Paroxetine.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Paroxetine.Approved, Vet Approved
CeritinibParoxetine may increase the QTc-prolonging activities of Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Paroxetine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Paroxetine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Paroxetine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Paroxetine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Paroxetine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Paroxetine.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Paroxetine.Approved, Vet Approved
ChlorothiazideParoxetine may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Paroxetine.Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Paroxetine.Experimental
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Paroxetine.Approved, Vet Approved
ChlorpropamideParoxetine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneParoxetine may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Paroxetine.Approved
CholecalciferolThe metabolism of Paroxetine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe metabolism of Cilostazol can be decreased when combined with Paroxetine.Approved
CimetidineThe metabolism of Paroxetine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Paroxetine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Paroxetine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Paroxetine.Approved, Investigational
CiprofloxacinParoxetine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideParoxetine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramParoxetine may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinParoxetine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Paroxetine can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Paroxetine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Paroxetine.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Paroxetine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Paroxetine.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Paroxetine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Paroxetine is combined with Clopenthixol.Experimental
CloranololThe serum concentration of Cloranolol can be increased when it is combined with Paroxetine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Paroxetine.Approved, Illicit
ClorindioneParoxetine may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Clothiapine.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Paroxetine.Approved, Illicit
ClotrimazoleThe metabolism of Paroxetine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Paroxetine.Approved
CobicistatThe serum concentration of Paroxetine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Paroxetine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Paroxetine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Paroxetine.Approved
CrizotinibParoxetine may increase the QTc-prolonging activities of Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Paroxetine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Cyclobenzaprine.Approved
CyclopenthiazideParoxetine may increase the hyponatremic activities of Cyclopenthiazide.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Paroxetine.Approved, Investigational
CyproheptadineThe therapeutic efficacy of Paroxetine can be decreased when used in combination with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Paroxetine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Paroxetine.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Paroxetine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Paroxetine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Paroxetine.Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Paroxetine.Approved, Investigational
DarunavirThe serum concentration of Paroxetine can be decreased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Paroxetine.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Paroxetine.Approved, Investigational
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Paroxetine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Paroxetine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Paroxetine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Paroxetine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Paroxetine.Vet Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Paroxetine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paroxetine.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Paroxetine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Paroxetine.Approved, Illicit, Investigational, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Paroxetine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Paroxetine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Paroxetine.Approved, Illicit
DextromethorphanParoxetine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Paroxetine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Paroxetine.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the serotonergic activities of Paroxetine.Approved, Investigational
DibenzepinThe risk or severity of adverse effects can be increased when Paroxetine is combined with Dibenzepin.Experimental
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Paroxetine.Approved, Vet Approved
DicoumarolParoxetine may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Paroxetine.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Paroxetine.Approved, Illicit
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Paroxetine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Paroxetine.Approved
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Paroxetine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Paroxetine.Experimental, Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Paroxetine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Paroxetine.Approved
DiphenadioneParoxetine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Paroxetine.Approved
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Paroxetine.Approved, Illicit
DisopyramideParoxetine may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Dixyrazine.Experimental
DofetilideParoxetine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronThe metabolism of Dolasetron can be decreased when combined with Paroxetine.Approved
DomperidoneParoxetine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Paroxetine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Paroxetine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Paroxetine.Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Paroxetine is combined with Dosulepin.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Paroxetine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Paroxetine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Paroxetine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Paroxetine.Approved, Investigational
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Paroxetine.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Paroxetine.Investigational
DronedaroneParoxetine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolParoxetine may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Paroxetine.Experimental, Illicit
DulaglutideParoxetine may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineDuloxetine may increase the serotonergic activities of Paroxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Paroxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Paroxetine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Paroxetine.Approved
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Paroxetine.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Paroxetine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Paroxetine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Paroxetine.Investigational
EmpagliflozinParoxetine may increase the hypoglycemic activities of Empagliflozin.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Paroxetine.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Paroxetine.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Paroxetine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Paroxetine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Paroxetine.Approved, Investigational
EpanololThe serum concentration of Epanolol can be increased when it is combined with Paroxetine.Experimental
EpinastineThe metabolism of Epinastine can be decreased when combined with Paroxetine.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Paroxetine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Paroxetine.Approved, Investigational
ErythromycinParoxetine may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramParoxetine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmirtazapineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Esmirtazapine.Investigational
EsmololThe serum concentration of Esmolol can be increased when it is combined with Paroxetine.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Paroxetine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Paroxetine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Paroxetine.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Paroxetine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Paroxetine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Paroxetine.Approved
Ethyl biscoumacetateParoxetine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Paroxetine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Paroxetine.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Paroxetine.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Paroxetine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Paroxetine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Paroxetine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Paroxetine.Approved
EtodolacParoxetine may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Paroxetine.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Paroxetine.Withdrawn
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Paroxetine.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Paroxetine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Paroxetine.Approved
ExenatideParoxetine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Paroxetine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Paroxetine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineParoxetine may increase the serotonergic activities of Fenfluramine.Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Paroxetine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Paroxetine.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Paroxetine.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Paroxetine.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Paroxetine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Paroxetine.Approved, Illicit
FluindioneParoxetine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Paroxetine.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Paroxetine.Approved, Illicit
FluoxetineParoxetine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolParoxetine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Paroxetine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Paroxetine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Paroxetine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Paroxetine.Approved
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Paroxetine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Paroxetine.Approved, Investigational
FosamprenavirThe serum concentration of Paroxetine can be decreased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of the active metabolites of Fosaprepitant can be reduced when Fosaprepitant is used in combination with Paroxetine resulting in a loss in efficacy.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Paroxetine.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Paroxetine.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Paroxetine is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Paroxetine.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Paroxetine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Paroxetine.Approved
Gadobenic acidParoxetine may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Paroxetine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Paroxetine.Approved, Illicit, Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Paroxetine.Approved, Investigational
GemifloxacinParoxetine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Paroxetine.Investigational
GliclazideParoxetine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideParoxetine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideParoxetine may increase the hypoglycemic activities of Glipizide.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Paroxetine.Approved, Illicit
GlyburideParoxetine may increase the hypoglycemic activities of Glyburide.Approved
GoserelinParoxetine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Paroxetine.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Paroxetine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Paroxetine.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Paroxetine.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Paroxetine.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Paroxetine.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Harmaline.Experimental
HeroinHeroin may increase the serotonergic activities of Paroxetine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Paroxetine.Approved
HydracarbazineHydracarbazine may increase the serotonergic activities of Paroxetine.Experimental
HydrochlorothiazideParoxetine may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Paroxetine resulting in a loss in efficacy.Approved, Illicit
HydroflumethiazideParoxetine may increase the hyponatremic activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Paroxetine.Approved, Illicit
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Paroxetine.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Paroxetine.Approved
IbutilideParoxetine may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Paroxetine.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Paroxetine.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Paroxetine.Approved
ImatinibThe metabolism of Imatinib can be decreased when combined with Paroxetine.Approved
ImipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Imipramine.Approved
IndalpineIndalpine may increase the serotonergic activities of Paroxetine.Investigational, Withdrawn
IndapamideParoxetine may increase the hyponatremic activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Paroxetine.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Paroxetine.Investigational
Insulin AspartParoxetine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirParoxetine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineParoxetine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineParoxetine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanParoxetine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproParoxetine may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Paroxetine.Approved, Investigational
Ioflupane I-123Paroxetine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Paroxetine.Approved
IprindoleThe risk or severity of adverse effects can be increased when Paroxetine is combined with Iprindole.Experimental
IproclozideIproclozide may increase the serotonergic activities of Paroxetine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Paroxetine.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Paroxetine is combined with Isocarboxazid.Approved
IsofluraneThe metabolism of Isoflurane can be decreased when combined with Paroxetine.Approved, Vet Approved
IsoniazidThe metabolism of Paroxetine can be decreased when combined with Isoniazid.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Paroxetine.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Paroxetine.Approved, Vet Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Paroxetine.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Paroxetine.Approved, Nutraceutical, Withdrawn
LabetalolThe metabolism of Labetalol can be decreased when combined with Paroxetine.Approved
LandiololThe serum concentration of Landiolol can be increased when it is combined with Paroxetine.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Paroxetine.Approved
LenvatinibParoxetine may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideParoxetine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Paroxetine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Paroxetine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Paroxetine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Paroxetine.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Paroxetine.Approved
LevofloxacinParoxetine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Paroxetine.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Paroxetine.Approved
LevorphanolLevorphanol may increase the serotonergic activities of Paroxetine.Approved
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Paroxetine.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Paroxetine.Approved, Vet Approved
LinezolidLinezolid may increase the serotonergic activities of Paroxetine.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Paroxetine.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Paroxetine.Approved
LiraglutideParoxetine may increase the hypoglycemic activities of Liraglutide.Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Paroxetine.Approved, Investigational
LithiumLithium may increase the serotonergic activities of Paroxetine.Approved
LofentanilLofentanil may increase the serotonergic activities of Paroxetine.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Lofepramine.Experimental
LomustineThe metabolism of Lomustine can be decreased when combined with Paroxetine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Paroxetine.Approved
LopinavirParoxetine may increase the QTc-prolonging activities of Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Paroxetine.Experimental
LoratadineThe metabolism of Loratadine can be decreased when combined with Paroxetine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Paroxetine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Paroxetine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Paroxetine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Loxapine.Approved
LumefantrineParoxetine may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibParoxetine may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Lurasidone.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Paroxetine.Approved, Vet Approved
MalathionThe metabolism of Malathion can be decreased when combined with Paroxetine.Approved, Investigational
ManidipineThe metabolism of Paroxetine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Paroxetine.Approved
MebanazineMebanazine may increase the serotonergic activities of Paroxetine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Paroxetine.Experimental
MecaserminParoxetine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Paroxetine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Paroxetine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Paroxetine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Paroxetine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Melperone.Approved, Investigational
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Paroxetine.Investigational, Withdrawn
MepindololThe serum concentration of Mepindolol can be increased when it is combined with Paroxetine.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Paroxetine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Paroxetine.Approved, Illicit
MeptazinolMeptazinol may increase the serotonergic activities of Paroxetine.Experimental
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Paroxetine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Paroxetine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Paroxetine.Approved
MetforminParoxetine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Paroxetine.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Paroxetine.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Paroxetine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Paroxetine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Paroxetine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Paroxetine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Paroxetine.Approved
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Paroxetine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Paroxetine.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Paroxetine.Approved
MethyclothiazideParoxetine may increase the hyponatremic activities of Methyclothiazide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Paroxetine.Experimental
Methylene blueParoxetine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Paroxetine.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Paroxetine.Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Paroxetine.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Paroxetine.Approved, Illicit, Withdrawn
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Paroxetine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Paroxetine.Approved, Investigational
MetolazoneParoxetine may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Paroxetine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Paroxetine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Paroxetine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Paroxetine.Approved, Investigational
MidostaurinThe metabolism of Paroxetine can be decreased when combined with Midostaurin.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Paroxetine.Approved, Investigational
MiglitolParoxetine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Paroxetine is combined with Milnacipran.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Paroxetine.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Paroxetine.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Mirtazapine.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Paroxetine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Paroxetine.Approved, Investigational, Withdrawn
MorphineThe metabolism of Morphine can be decreased when combined with Paroxetine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Mosapramine.Experimental
MoxifloxacinParoxetine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Paroxetine.Approved, Investigational
NabumetoneParoxetine may increase the antiplatelet activities of Nabumetone.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Paroxetine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Paroxetine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Paroxetine is combined with Naratriptan.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Paroxetine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Paroxetine.Approved, Investigational
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Paroxetine.Approved, Withdrawn
NetupitantThe metabolism of Netupitant can be decreased when combined with Paroxetine.Approved
NevirapineThe metabolism of Nevirapine can be decreased when combined with Paroxetine.Approved
NialamideNialamide may increase the serotonergic activities of Paroxetine.Withdrawn
NicardipineThe metabolism of Nicardipine can be decreased when combined with Paroxetine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Paroxetine.Approved, Investigational
NicomorphineNicomorphine may increase the serotonergic activities of Paroxetine.Experimental
NicotineThe metabolism of Nicotine can be decreased when combined with Paroxetine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Paroxetine.Approved
NilotinibParoxetine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Paroxetine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Paroxetine.Approved, Investigational, Vet Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Paroxetine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Paroxetine.Investigational
NormethadoneNormethadone may increase the serotonergic activities of Paroxetine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Nortriptyline.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Paroxetine.Withdrawn
OfloxacinParoxetine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Paroxetine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Paroxetine.Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Paroxetine.Approved
OpipramolThe risk or severity of adverse effects can be increased when Paroxetine is combined with Opipramol.Investigational
OpiumOpium may increase the serotonergic activities of Paroxetine.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Paroxetine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Paroxetine is combined with Osanetant.Investigational
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Paroxetine.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Paroxetine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Paroxetine.Approved, Investigational
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Paroxetine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Paroxetine.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Paroxetine.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Paroxetine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Oxypertine.Experimental
PaliperidoneParoxetine may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Paroxetine.Approved, Investigational
PanobinostatThe serum concentration of Paroxetine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Paroxetine.Approved, Investigational
ParecoxibParoxetine may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Paroxetine.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Paroxetine.Approved
Peginterferon alfa-2bThe serum concentration of Paroxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Paroxetine is combined with Penfluridol.Experimental
PentamidineThe metabolism of Pentamidine can be decreased when combined with Paroxetine.Approved
PentazocinePentazocine may increase the serotonergic activities of Paroxetine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Paroxetine.Approved, Vet Approved
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Paroxetine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Paroxetine.Investigational
PerflutrenParoxetine may increase the QTc-prolonging activities of Perflutren.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Paroxetine.Approved, Investigational
PermethrinThe metabolism of Permethrin can be decreased when combined with Paroxetine.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Paroxetine.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Paroxetine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Paroxetine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Paroxetine.Withdrawn
PhenazocinePhenazocine may increase the serotonergic activities of Paroxetine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Phenelzine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Paroxetine.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Paroxetine.Experimental
PhenindioneParoxetine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Paroxetine.Withdrawn
PhenoperidinePhenoperidine may increase the serotonergic activities of Paroxetine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Paroxetine.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Paroxetine.Withdrawn
PhenprocoumonParoxetine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Paroxetine.Approved
PioglitazoneParoxetine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Pipamperone.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Paroxetine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Paroxetine.Approved, Investigational
PiritramidePiritramide may increase the serotonergic activities of Paroxetine.Investigational
PirlindolePirlindole may increase the serotonergic activities of Paroxetine.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Paroxetine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Paroxetine.Approved
PolythiazideParoxetine may increase the hyponatremic activities of Polythiazide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Paroxetine.Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Paroxetine.Approved
PramlintideParoxetine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Paroxetine.Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Paroxetine.Approved
PravastatinThe risk or severity of adverse effects can be increased when Pravastatin is combined with Paroxetine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Paroxetine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Paroxetine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Paroxetine.Approved
PrimaquineParoxetine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Paroxetine.Approved, Vet Approved
ProcainamideParoxetine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Paroxetine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Procarbazine.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Paroxetine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Paroxetine.Approved, Vet Approved
PromazineParoxetine may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe metabolism of Promethazine can be decreased when combined with Paroxetine.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Paroxetine.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Paroxetine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Paroxetine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Propericiazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Paroxetine.Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Paroxetine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Paroxetine.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Paroxetine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Paroxetine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Paroxetine.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Paroxetine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Paroxetine.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Paroxetine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Paroxetine.Approved, Illicit
QuetiapineParoxetine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinethazoneParoxetine may increase the hyponatremic activities of Quinethazone.Approved
QuinidineParoxetine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineParoxetine may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Paroxetine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Paroxetine.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Paroxetine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Paroxetine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Rasagiline.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Paroxetine.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Paroxetine.Approved, Withdrawn
RepaglinideParoxetine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Paroxetine.Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Paroxetine.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Paroxetine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ritanserin.Investigational
RitonavirThe metabolism of Paroxetine can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Paroxetine is combined with Rizatriptan.Approved
RofecoxibParoxetine may increase the antiplatelet activities of Rofecoxib.Investigational, Withdrawn
RolapitantThe metabolism of Paroxetine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Paroxetine.Vet Approved
RopiniroleThe metabolism of Paroxetine can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Paroxetine.Approved
RosiglitazoneParoxetine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineThe metabolism of Rotigotine can be decreased when combined with Paroxetine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Paroxetine.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Paroxetine.Approved
SafrazineSafrazine may increase the serotonergic activities of Paroxetine.Withdrawn
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Paroxetine.Approved, Investigational
SaxagliptinParoxetine may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Paroxetine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Paroxetine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Paroxetine.Investigational
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Paroxetine.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Paroxetine.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Paroxetine.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Paroxetine.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Paroxetine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Paroxetine.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Paroxetine.Approved
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Paroxetine.Approved
SotalolParoxetine may increase the QTc-prolonging activities of Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Paroxetine.Experimental
StiripentolThe metabolism of Paroxetine can be decreased when combined with Stiripentol.Approved
SufentanilSufentanil may increase the serotonergic activities of Paroxetine.Approved, Investigational
SulfadiazineParoxetine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleParoxetine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleParoxetine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Paroxetine.Approved, Investigational
SunitinibParoxetine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Paroxetine.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Paroxetine.Approved, Investigational
TalinololThe serum concentration of Talinolol can be increased when it is combined with Paroxetine.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Paroxetine resulting in a loss in efficacy.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Paroxetine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Paroxetine.Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Paroxetine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Paroxetine.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Paroxetine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Paroxetine.Investigational, Withdrawn
TelavancinParoxetine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinParoxetine may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Paroxetine.Approved
TerbinafineThe metabolism of Paroxetine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Paroxetine.Withdrawn
TertatololThe serum concentration of Tertatolol can be increased when it is combined with Paroxetine.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Paroxetine.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Paroxetine.Approved, Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Paroxetine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Paroxetine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Paroxetine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Paroxetine.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Paroxetine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Paroxetine.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Paroxetine.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Paroxetine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Paroxetine.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Paroxetine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Paroxetine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Thiothixene.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Paroxetine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Paroxetine.Approved
TianeptineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Paroxetine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Paroxetine.Vet Approved
TilidineTilidine may increase the serotonergic activities of Paroxetine.Experimental
TimololThe metabolism of Timolol can be decreased when combined with Paroxetine.Approved
TioclomarolParoxetine may increase the anticoagulant activities of Tioclomarol.Experimental
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Paroxetine.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Paroxetine.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Paroxetine.Approved
TolazamideParoxetine may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideParoxetine may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Paroxetine.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Paroxetine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Paroxetine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Paroxetine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Paroxetine.Approved, Investigational
ToremifeneParoxetine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Paroxetine.Approved, Investigational
TramadolParoxetine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Paroxetine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Tranylcypromine.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Paroxetine.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Paroxetine.Approved, Investigational, Nutraceutical
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Paroxetine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Paroxetine.Vet Approved
TrichlormethiazideParoxetine may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Paroxetine.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Paroxetine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Paroxetine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Paroxetine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Paroxetine.Approved
TropisetronTropisetron may increase the serotonergic activities of Paroxetine.Approved, Investigational
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Paroxetine.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Paroxetine.Approved, Investigational
ValdecoxibParoxetine may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Paroxetine.Approved, Investigational
VandetanibParoxetine may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibParoxetine may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Paroxetine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Veralipride.Experimental
VernakalantThe metabolism of Vernakalant can be decreased when combined with Paroxetine.Approved, Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Paroxetine.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Paroxetine.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Paroxetine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Paroxetine.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Paroxetine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Paroxetine.Experimental
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Paroxetine.Approved
WarfarinParoxetine may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Paroxetine.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Paroxetine.Vet Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Paroxetine.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Paroxetine.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Paroxetine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Paroxetine.Approved
ZimelidineParoxetine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneParoxetine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Paroxetine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Paroxetine.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Paroxetine.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Paroxetine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Paroxetine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Zotepine.Approved, Investigational
ZuclopenthixolParoxetine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Avoid alcohol.

References

Synthesis Reference

Charles M. Zepp, Yun Gao, Donald L. Heefner, "Method of preparing optically pure precursors of paroxetine." U.S. Patent US5258517, issued January, 1976.

US5258517
General References
  1. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 Nov;19(6):567-96. [PubMed:16272179]
  2. Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M: Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry. 1999 Aug;175:120-6. [PubMed:10627793]
  3. Yonkers KA, Gullion C, Williams A, Novak K, Rush AJ: Paroxetine as a treatment for premenstrual dysphoric disorder. J Clin Psychopharmacol. 1996 Feb;16(1):3-8. [PubMed:8834412]
  4. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B: Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol. 1998 Aug;18(4):274-81. [PubMed:9690692]
  5. Waldinger MD, Zwinderman AH, Olivier B: SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. J Clin Psychopharmacol. 2001 Dec;21(6):556-60. [PubMed:11763001]
External Links
Human Metabolome Database
HMDB14853
KEGG Drug
D02362
KEGG Compound
C07415
PubChem Compound
43815
PubChem Substance
46504821
ChemSpider
39888
BindingDB
50331515
ChEBI
7936
ChEMBL
CHEMBL490
Therapeutic Targets Database
DAP001428
PharmGKB
PA450801
HET
8PR
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Paroxetine
ATC Codes
N06AB05 — Paroxetine
AHFS Codes
  • 28:16.04.20 — Selective-serotonin Reuptake Inhibitors
PDB Entries
3v5w / 4jlt / 4l9i / 4mm4 / 5i6x / 6awn
FDA label
Download (299 KB)
MSDS
Download (51.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailableDrug-Drug Interaction (DDI)1
1CompletedNot AvailableHealthy Volunteers8
1CompletedNot AvailableMetabolic Detoxication, Phase I1
1CompletedBasic ScienceAnovulatory cycle / Cytochrome P450 CYP3A Enzyme Deficiency / Disorder Due Cytochrome P450 CYP2D6 Variant1
1CompletedDiagnosticDepressive Disorders / Healthy Volunteers / Two Single Doses of Controlled Release Paroxetine Given 14 Days Apart1
1CompletedOtherDepressive Disorders / Healthy Volunteers1
1CompletedTreatmentDiabetic Neuropathies / Fibromyalgia / Major Depressive Disorder (MDD) / Vasomotor Symptoms1
1CompletedTreatmentHealthy Adults1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentPostmenopausal Syndrome1
1, 2CompletedTreatmentFibromyalgia1
1, 2CompletedTreatmentHIV Associated Neurocognitive Disorders (HAND)1
2Active Not RecruitingTreatmentMajor Depressive Disorder (MDD)1
2CompletedPreventionMenopausal Hot Flushes1
2CompletedTreatmentAnxiety Disorders2
2CompletedTreatmentAnxiety Disorders / Social Anxiety Disorder (SAD)1
2CompletedTreatmentDepressive Disorder and Anxiety Disorders / Social Anxiety Disorder (SAD)1
2CompletedTreatmentDepressive Disorders1
2CompletedTreatmentDepressive State / Parkinson's Disease (PD)1
2CompletedTreatmentMajor Depressive Disorder (MDD)3
2CompletedTreatmentSocial Anxiety Disorder (SAD) / Social Phobia2
2CompletedTreatmentSocial Phobia1
2CompletedTreatmentTinnitus1
2RecruitingTreatmentCardiac Remodeling / Myocardial Infarction (MI)1
2TerminatedNot AvailableDepressive State / Hepatitis C Infection1
2TerminatedTreatmentMajor Depressive Disorder With Panic Attacks / Panic Disorders1
2TerminatedTreatmentPost-Traumatic Stress Disorder (PTSD)1
3CompletedNot AvailablePremenstrual Dysphoric Disorder1
3CompletedTreatmentAlcoholism / Depressive State / PTSD1
3CompletedTreatmentBipolar Disorder (BD) / Depression, Bipolar / Depressive State1
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
3CompletedTreatmentDepressive Disorders1
3CompletedTreatmentDepressive State1
3CompletedTreatmentDepressive State / Parkinson's Disease (PD)1
3CompletedTreatmentDisseminated Sclerosis / Pain, Neuropathic1
3CompletedTreatmentGeneralized Anxiety Disorder (GAD)1
3CompletedTreatmentMajor Depressive Disorder (MDD)9
3CompletedTreatmentMenopausal Hot Flushes1
3CompletedTreatmentPTSD1
3CompletedTreatmentPanic Disorders1
3CompletedTreatmentPost-Traumatic Stress Disorder (PTSD)1
3CompletedTreatmentPostmenopausal Syndrome1
3CompletedTreatmentPremature Ejaculation1
3CompletedTreatmentSocial Anxiety Disorder (SAD)1
3CompletedTreatmentUnipolar Depression1
3TerminatedTreatmentAnxiety Disorders1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentGeneralized Anxiety Disorder (GAD)3
3TerminatedTreatmentMajor Depressive Disorder (MDD)1
4Active Not RecruitingTreatmentHealthy Volunteers1
4CompletedNot AvailableDepressive State1
4CompletedNot AvailableMajor Depressive Disorder (MDD)1
4CompletedBasic SciencePost-Traumatic Stress Disorder (PTSD)1
4CompletedBasic SciencePosttraumatic Stress Disorder (PTSD)1
4CompletedHealth Services ResearchObsessive Compulsive Disorder (OCD)1
4CompletedOtherHealthy Controls / Major Depressive Disorder (MDD)1
4CompletedPreventionStress Disorders, Post-Traumatic1
4CompletedTreatmentAlcohol Abuse / Alcohol Dependence / Alcohol Use Disorder (AUD) / Social Anxiety Disorder (SAD) / Social Phobia1
4CompletedTreatmentBipolar Disorder (BD)1
4CompletedTreatmentCombat Disorders / Stress Disorders, Post-Traumatic1
4CompletedTreatmentDementias1
4CompletedTreatmentDepressive State2
4CompletedTreatmentDepressive State / Hypertensive1
4CompletedTreatmentDepressive State / Primary Insomnia1
4CompletedTreatmentDepressive State / Suicidal Ideation1
4CompletedTreatmentFear of open spaces / Panic Disorders1
4CompletedTreatmentFibromyalgia Syndrome1
4CompletedTreatmentIrritable Bowel Syndrome (IBS)1
4CompletedTreatmentMajor Depressive Disorder (MDD)5
4CompletedTreatmentMenopause1
4CompletedTreatmentObstructive Sleep Apnea (OSA)1
4CompletedTreatmentPTSD1
4CompletedTreatmentPanic Disorders4
4CompletedTreatmentPhobic Disorders1
4CompletedTreatmentPost Traumatic Stress Disorder (PTSD)1
4CompletedTreatmentPosttraumatic Stress Disorders1
4CompletedTreatmentPremenstrual Dysphoric Disorder / Premenstrual Syndrome1
4CompletedTreatmentPsychiatric Disorder NOS1
4CompletedTreatmentUnipolar Depression1
4RecruitingNot AvailableDepressive Disorders / Lactation1
4RecruitingTreatmentAnxiety Disorders / Obsessive-Compulsive Disorder (OCD) / Psychiatric Disorder NOS1
4RecruitingTreatmentCardiovascular Risk Factors / Endothelial Dysfunction / Postmenopausal Flushing1
4RecruitingTreatmentGeneralized Anxious Disorders1
4TerminatedTreatmentDepressive Disorders1
4TerminatedTreatmentDepressive State1
4TerminatedTreatmentMajor Depressive Disorder (MDD)1
4TerminatedTreatmentPosttraumatic Stress Disorder (PTSD)1
4Unknown StatusNot AvailableMajor Depressive Disorder (MDD)1
4Unknown StatusTreatmentDepressive State / Pain1
4Unknown StatusTreatmentMajor Depression Disorder1
4Unknown StatusTreatmentMajor Depressive Disorder (MDD)2
Not AvailableActive Not RecruitingNot AvailableAnxiety Disorders / Generalized Anxiety Disorder (GAD) / Obsessive-Compulsive Disorder (OCD) / Panic Disorders / Post-Traumatic Stress Disorder (PTSD) / Social Anxiety Disorder (SAD)1
Not AvailableActive Not RecruitingNot AvailableMajor Depressive Disorder (MDD)1
Not AvailableActive Not RecruitingBasic ScienceHealthy Volunteers1
Not AvailableActive Not RecruitingTreatmentAdverse Reaction to Drug / Continuous Antidepressant Abuse / Depressive State1
Not AvailableActive Not RecruitingTreatmentDepressive State2
Not AvailableCompletedNot AvailableAcute Kidney Injury (AKI) / Depressive State1
Not AvailableCompletedNot AvailablePanic Disorders2
Not AvailableCompletedNot AvailablePsychiatric Disorder NOS3
Not AvailableCompletedNot AvailableSocial Phobia1
Not AvailableCompletedBasic ScienceAnxiety Disorders1
Not AvailableCompletedBasic ScienceMajor Depressive Disorder (MDD)1
Not AvailableCompletedPreventionChronic Hepatitis C Infection / Depressive State / Interferon-alpha Associated Side Effects1
Not AvailableCompletedTreatmentBipolar Disorder (BD)1
Not AvailableCompletedTreatmentDepressive State1
Not AvailableCompletedTreatmentMajor Depression With Panic Attacks / Panic Disorders1
Not AvailableCompletedTreatmentSleep disorders and disturbances / Stress Disorders, Post-Traumatic1
Not AvailableCompletedTreatmentTobacco Use Disorders1
Not AvailableCompletedTreatmentUnipolar Depression1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingNot AvailableObsessive-Compulsive Disorder (OCD)1
Not AvailableRecruitingTreatmentAdverse Reaction to Drug / Depressive State1
Not AvailableRecruitingTreatmentAlcohol-Related Disorders / Brain Injury / Chronic Diseases / Depressive State / Mild Cognitive Impairment (MCI) / Pain / Posttraumatic Stress Disorders / Quality of Life / Substance-Related Disorders / Suicidal Ideation / Wounds and Injuries1
Not AvailableRecruitingTreatmentAntidepressant Drug Adverse Reaction / Depressive State1
Not AvailableRecruitingTreatmentDepressive State / Depressive Symptoms1
Not AvailableTerminatedTreatmentMenopausal Hot Flushes1
Not AvailableTerminatedTreatmentSleep disorders and disturbances / Stress Disorders, Post-Traumatic1
Not AvailableUnknown StatusNot AvailableHealthy Volunteers1
Not AvailableUnknown StatusTreatmentAnxiety Disorders / Panic Disorders / Psychiatric Disorder NOS1
Not AvailableUnknown StatusTreatmentMajor Depressive Disorder (MDD)1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1
Not AvailableWithdrawnTreatmentPost-Traumatic Stress Disorder (PTSD)1

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline
  • Apotex inc
  • Mylan pharmaceuticals inc
  • Actavis elizabeth llc
  • Alphapharm pty ltd
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Zydus pharmaceuticals usa inc
  • Noven therapeutics llc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral7.5 mg/1
TabletOral10 mg/1
TabletOral30 mg/1
TabletOral40 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral40 mg/1
TabletOral20 mg/1
SuspensionOral10 mg/5mL
Tablet, film coatedOral30 mg/1
Tablet, extended releaseOral12.5 mg
Tablet, extended releaseOral25 mg
Tablet, extended releaseOral37.5 mg
Tablet, film coated, extended releaseOral12.5 mg/1
Tablet, film coated, extended releaseOral25 mg/1
TabletOral10 mg
TabletOral20 mg
TabletOral30 mg
Tablet, film coated, extended releaseOral37.5 mg/1
TabletOral40 mg
Prices
Unit descriptionCostUnit
Paxil 30 40 mg tablet Bottle138.39USD bottle
Paxil 30 30 mg tablet Bottle131.0USD bottle
Paxil 30 10 mg tablet Bottle121.87USD bottle
Pexeva 40 mg tablet6.29USD tablet
Pexeva 30 mg tablet6.11USD tablet
Pexeva 20 mg tablet5.84USD tablet
Pexeva 10 mg tablet5.6USD tablet
Paxil CR 37.5 mg 24 Hour tablet4.5USD tablet
Paxil 40 mg tablet4.44USD tablet
Paxil CR 25 mg 24 Hour tablet4.37USD tablet
Paxil cr 37.5 mg tablet4.32USD tablet
Paxil 30 mg tablet4.2USD tablet
Paxil cr 25 mg tablet4.2USD tablet
Paxil CR 12.5 mg 24 Hour tablet4.18USD tablet
Paxil 20 mg tablet4.16USD tablet
PARoxetine HCl 37.5 mg 24 Hour tablet4.04USD tablet
Paxil cr 12.5 mg tablet4.02USD tablet
PARoxetine HCl 25 mg 24 Hour tablet3.93USD tablet
Paxil 10 mg tablet3.91USD tablet
PARoxetine HCl 12.5 mg 24 Hour tablet3.76USD tablet
Paroxetine hcl 40 mg tablet2.93USD tablet
Paroxetine hcl 30 mg tablet2.78USD tablet
Paroxetine hcl 20 mg tablet2.7USD tablet
Paroxetine hcl 10 mg tablet2.58USD tablet
Paxil 30 mg Tablet2.16USD tablet
Pms-Paroxetine 40 mg Tablet2.1USD tablet
Paxil 20 mg Tablet2.03USD tablet
Apo-Paroxetine 30 mg Tablet1.12USD tablet
Co Paroxetine 30 mg Tablet1.12USD tablet
Mylan-Paroxetine 30 mg Tablet1.12USD tablet
Novo-Paroxetine 30 mg Tablet1.12USD tablet
Phl-Paroxetine 30 mg Tablet1.12USD tablet
Pms-Paroxetine 30 mg Tablet1.12USD tablet
Ratio-Paroxetine 30 mg Tablet1.12USD tablet
Sandoz Paroxetine 30 mg Tablet1.12USD tablet
Apo-Paroxetine 20 mg Tablet1.05USD tablet
Co Paroxetine 20 mg Tablet1.05USD tablet
Mylan-Paroxetine 20 mg Tablet1.05USD tablet
Novo-Paroxetine 20 mg Tablet1.05USD tablet
Phl-Paroxetine 20 mg Tablet1.05USD tablet
Pms-Paroxetine 20 mg Tablet1.05USD tablet
Ratio-Paroxetine 20 mg Tablet1.05USD tablet
Sandoz Paroxetine 20 mg Tablet1.05USD tablet
Paxil 10 mg/5ml Suspension0.85USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6703408No2002-10-212022-10-21Us
US5789449No1992-07-062009-07-06Us
CA2445678No2009-11-242016-07-19Canada
CA2168829No1997-12-162016-02-05Canada
US7598271No2003-02-122023-02-12Us
US6121291Yes1997-09-172017-09-17Us
US5811436Yes1996-03-222016-03-22Us
US6063927Yes1999-10-232019-10-23Us
US6172233Yes1998-07-152018-07-15Us
US7229640Yes1997-01-192017-01-19Us
US6548084Yes1997-01-192017-01-19Us
US5874447No1997-06-102017-06-10Us
US8658663No2009-04-062029-04-06Us
US8946251No2006-08-042026-08-04Us
US6133289Yes1995-11-192015-11-19Us
US5900423Yes1995-11-192015-11-19Us
US5872132Yes1995-11-192015-11-19Us
US6080759Yes1995-11-192015-11-19Us
US9393237No2006-08-042026-08-04Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)147-150 °C (mesylate salt) FDA label
water solubility>1 g/mL (mesylate salt) Not Available
logP3.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00853 mg/mLALOGPS
logP3.1ALOGPS
logP3.15ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)9.77ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area39.72 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity88.02 m3·mol-1ChemAxon
Polarizability34.48 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9869
Caco-2 permeable+0.5195
P-glycoprotein substrateSubstrate0.6555
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.6771
Renal organic cation transporterInhibitor0.5222
CYP450 2C9 substrateNon-substrate0.9265
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6004
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.8298
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8649
Ames testNon AMES toxic0.6722
CarcinogenicityNon-carcinogens0.9046
BiodegradationNot ready biodegradable0.995
Rat acute toxicity2.8239 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5554
hERG inhibition (predictor II)Non-inhibitor0.5879
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0006-8900000000-0a273deac3c7836cdc76
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-3709000000-7d029049c2e6d638ecbe
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-2409000000-077fb077fbf0e4210f51

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Phenylpiperidines
Direct Parent
Phenylpiperidines
Alternative Parents
Benzodioxoles / Fluorobenzenes / Aralkylamines / Alkyl aryl ethers / Aryl fluorides / Oxacyclic compounds / Dialkylamines / Azacyclic compounds / Acetals / Organopnictogen compounds
show 2 more
Substituents
Phenylpiperidine / Benzodioxole / Alkyl aryl ether / Fluorobenzene / Halobenzene / Aralkylamine / Aryl fluoride / Aryl halide / Monocyclic benzene moiety / Benzenoid
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
piperidines, organofluorine compound, aromatic ether, benzodioxoles (CHEBI:7936)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH: Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharmacol Exp Ther. 2000 Jun;293(3):870-8. [PubMed:10869387]
  2. Preuss UW, Soyka M, Bahlmann M, Wenzel K, Behrens S, de Jonge S, Kruger M, Bondy B: Serotonin transporter gene regulatory region polymorphism (5-HTTLPR), [3H]paroxetine binding in healthy control subjects and alcohol-dependent patients and their relationships to impulsivity. Psychiatry Res. 2000 Sep 25;96(1):51-61. [PubMed:10980326]
  3. Haughey HM, Fleckenstein AE, Metzger RR, Hanson GR: The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia. J Neurochem. 2000 Oct;75(4):1608-17. [PubMed:10987842]
  4. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology. 2000 Nov;23(5):587-90. [PubMed:11027924]
  5. Wihlback AC, Sundstrom-Poromaa I, Allard P, Mjorndal T, Spigset O, Backstrom T: Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin 2A receptor binding. Obstet Gynecol. 2001 Sep;98(3):450-7. [PubMed:11530128]
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Rubin RT: Paroxetine binding to the rat norepinephrine transporter in vivo. Biol Psychiatry. 2000 Nov 1;48(9):954-6. [PubMed:11203183]
  2. Gilmor ML, Owens MJ, Nemeroff CB: Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry. 2002 Oct;159(10):1702-10. [PubMed:12359676]
  3. Nemeroff CB, Owens MJ: Neuropharmacology of paroxetine. Psychopharmacol Bull. 2003 Spring;37 Suppl 1:8-18. [PubMed:14566196]
  4. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Bixo M, Allard P, Backstrom T, Mjorndal T, Nyberg S, Spigset O, Sundstrom-Poromaa I: Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment. Psychoneuroendocrinology. 2001 Aug;26(6):551-64. [PubMed:11403977]
  2. Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, Wilson AA, Rafi-Tari S, Mayberg HS, Kennedy SH: The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry. 2001 Jan;158(1):78-85. [PubMed:11136637]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]

Enzymes

Details
1. Cytochrome P450 2D6
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577]
  2. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657]
  3. Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W: Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther. 1997 Sep;62(3):334-47. [PubMed:9333110]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369]

Drug created on June 13, 2005 07:24 / Updated on November 16, 2017 13:31